Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-09-23 (bizjournals.com)
Biogen, Alnylam-partnered Camp4 Therapeutics unveils IPO plans
The Cambridge biotech is the latest to join the fall frenzy of biotechs making moves to go public, after a summer break in IPO activity.
Read more
2024-03-08 (teleborsa.it)
Wall Street weak. Job Report strengthens expectations on the Fed
The New York Stock Exchange remains at around parity, with the Dow Jones standing at 38,804 points, while, on the contrary, the S&P-500 has a trend...
Read more
2024-02-23 (ariva.de)
Minimal price discount for the Biogen share (€205.4700)
Biogen shares are currently unremarkable on the US stock market. The paper is currently trading at $222.34.
Read more
2023-11-21 (goingpublic.de)
“We address several points relevant to illnesses”
“We address several disease-relevant points” - Interview with Frank Weber, CEO, Vivoryon Therapeutics
Read more
2023-08-13 (indiatimes.com)
Biogen Inc. IPO
Biogen Inc. IPO - Read Biogen Inc. IPO Review and Analysis on The Economic Times. Find out Biogen Inc. IPO Issue Price, Subscription Dates and Status, Biogen Inc. IPO Listing Date and more.
Read more
2023-05-16 (finanznachrichten.de)
Biogen share price down today
In US securities trading, Biogen's shares are trading lighter at the moment. The security is currently trading at $308.21. The Biogen share has today on the US stock exchange
Read more
2022-12-14 (endpts.com)
Prothena hopes to raise $180M after Eisai Alzheimer's data prompted stock surge
Dublin-based Prothena has opened up 3 million of its common shares via an underwritten public offering, trading under the ticker $PRTA. Underwriters get 30 days to grab another 15% of the number of shares sold. That's a $180 million raise as of today, with Prothena's stock trading at $60 per
Read more
2021-07-01 (medcitynews.com)
All in on amyloid, Acumen Pharma’s IPO raises $160M for Alzheimer’s drug RD
Acumen Pharmaceuticals’ IPO raised $160 million to fund clinical development of its Alzheimer’s disease drug candidate. Though that drug goes after the same target as Biogen’s recently approved Aduhelm, Acumen says its antibody has potential dosing and safety advantages.
Read more
2021-06-25 (fiercebiotech.com)
Alzheimer's biotech Acumen prices $125M IPO, targets phase 2 data on amyloid-beta prospect
Acumen Pharmaceuticals has set the terms for its IPO, teeing it up to raise around $1 | Acumen Pharmaceuticals has set the terms for its IPO, teeing it up to raise around $125 million to take an antibody against amyloid-beta oligomers to the end of phase 2 in Alzheimer’s disease.
Read more
2021-06-08 (trend-online.com)
US stock market: start of the week in no particular order, Biogen soars
The New York Stock Exchange closed the first session of the week without major changes.
Read more
2016-08-12 (biopharma-reporter.com)
Samsung Biologics starts IPO process, discloses 2015 revenue and names Benepali as main product
Samsung Biologics has requested approval to list on the South Korea KOSPI exchange.
Read more